Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.47 |
| ▸ | CYP2C8 | P10632 | 5/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2437495 | 0.91 | CYP2C8 (0.45) | CYP3A4CYP2C8KCNH2NR1I2 | |
| SCHEMBL2439621 | 0.88 | CYP2C8 (0.58) | CYP3A4CYP2C8KCNH2NR1I2 | |
| SCHEMBL2370188 | 0.87 | CYP3A4 (0.48) | CYP3A4CYP2C8KCNH2NR1I2 | |
| SCHEMBL1920027 | 0.87 | CYP2C8 (0.48) | CYP3A4CYP2C8KCNH2NR1I2 | |
| SCHEMBL2369901 | 0.86 | CYP3A4 (0.47) | CYP3A4CYP2C8KCNH2NR1I2 | |
| SCHEMBL2437489 | 0.86 | CYP2C8 (0.45) | CYP3A4CYP2C8KCNH2NR1I2 | |
| SCHEMBL1918804 | 0.86 | CYP2C8 (0.54) | CYP3A4CYP2C8KCNH2NR1I2 | |
| SCHEMBL2370086 | 0.86 | CYP3A4 (0.49) | CYP3A4CYP2C8KCNH2NR1I2 | |
| SCHEMBL2369857 | 0.85 | CYP3A4 (0.48) | CYP3A4CYP2C8KCNH2NR1I2 | |
| SCHEMBL2369824 | 0.85 | CYP3A4 (0.46) | CYP3A4CYP2C8KCNH2NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2545051-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2013-01-16 | — | — | EP | claimed |
| WO-2011112769-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-15 | — | — | WO | claimed |
| EP-2545051-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2013-01-16 | — | — | EP | disclosed |
| WO-2011112769-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-15 | — | — | WO | disclosed |